Clinical trial · no report yet · Phase 3
EMERALD-3
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- NCT05301842 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 68 | |
| YouTube | 33 | |
| Podcasts | 20 | |
| Bluesky threads | 3 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Tremelimumab; Durvalumab; Transarterial Chemoembolization (TACE); Lenvatinib
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Active comparator
- Enrollment
- 760
- Primary outcomes
- Progression Free Survival (PFS) for Arm A vs Arm C
- Sponsor
- AstraZeneca
- Start
- Mar 28, 2022
- Primary completion
- Feb 23, 2026
- Results posted
- No
- Registry record
- NCT05301842 · updated Oct 16, 2026
Publications
linked from the registry- Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J; EMERALD-3 Investigators. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol. 2026 Sep;27(9):1077-1093. doi: 10.1016/S1470-2045(26)00278-0. PubMed 42636832